ClinicalTrials.Veeva

Menu

Magnesium Sulfate Versus Placebo for Tocolysis in PPROM

R

Regional Obstetrical Consultants

Status

Terminated

Conditions

Preterm Premature Rupture of Membranes

Treatments

Drug: Magnesium sulfate

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Study compares the outcomes of women between 26 and 32 wks gestation with rupture of membranes. Women randomized to receive tocolysis with magnesium sulfate x 48 hrs or placebo of saline IV x 48 hrs. Antibiotics and antenatal steroids given to both groups.

Full description

The majority of studies of the effectiveness of tocolysis with PPROM were in the 1980s prior to the commmon usage of antenatal steroids and prophylactic maternal antibiotics. In most studies, tocolysis was not attempted prior to the onset of labor in this group of women. The ACOG Practice Bulletin of June 1998 concedes that the recommendation of tocolysis to permit administration of steroids and maternal antibiotics is based primarily upon consensus, not consistent scientific evidence.

The purpose of this study, which will randomize 128 subjects to tocolysis or no tocolysis, is to prospectively assess whether short term (48 hr) tocolysis affords benefit to women and babies between 26 and 32 weeks gestation with PPROM.

Subjects will be enrolled at 1-2 high risk hospitals in Chattanooga and Knoxville. All English and Spanish speaking women 18-45 years with PPROM and cervical dilation <4 will be eligible. Women with suspected intrauterine infection, positive fetal lung maturity, or > 6 hours tocolysis at time of admission will be excluded.

Both groups of women will receive continuous fetal monitoring, antibiotics, and antenatal steroids (if not previously administered). Both groups will be evaluated every 2-4 hours for fetal and maternal well being. Both groups will receive IVF at 125cc/hr, and the treatment group will be loaded with 4 grams of magnesium sulfate and receive maintainence dose of 2 grams/hr x 48 hrs.

Enrollment

4 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • English or Spanish speaking
  • preterm premature rupture of membranes
  • 26 - 32.6 weeks gestation
  • cervical dilation </= 4 cm

Exclusion criteria

  • suspected intrauterine or intraamniotic infection
  • > 6 hours of tocolysis prior to admission
  • positive fetal lung maturity

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

4 participants in 2 patient groups, including a placebo group

Magnesium sulfate
Active Comparator group
Description:
x 48 hours IV
Treatment:
Drug: Magnesium sulfate
Normal saline
Placebo Comparator group
Description:
x 48 hours IV
Treatment:
Drug: Magnesium sulfate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems